There are number of new and emerging antiretroviral agents for the treatment of HIV. Dr Amesika Nyaku (Rutgers New Jersey Medical School, Newark, NJ, USA) discusses different antiretroviral therapies, including long-acting cabotegravir and long-acting rilivirine, the use of fostemsavir and in whom this treatment benefits most, and management of missed doses.
View more content from Dr Amesika Nyaku: Future directions in HIV research
The presentation entitled: ‘New Antiretroviral Agents and When to Use Them’ was presented at the American Conference for the Treatment of HIV (ACTHIV), May 5-7, 2022.
- What is the mechanism of action of the long-acting cabotegravir and long-acting rilpivirine? (0:16)
- What are the cautions/contraindications of these drugs? (1:33)
- How should missed doses be managed? (3:28)
- Could you tell us a little about fostemsavir and the patients most likely to benefit from it? (6:31)
Disclosures: Amesika Nyaku has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Share this Video
Related Videos In HIV
Moti Ramgopal, IDWeek 2022: Unmet needs and challenges around maintenance of HIV-1 virologic suppression
In this touchINFECTIOUS DISEASES interview, we met with Dr Moti Ramgopal (Midway Research Center, FL, USA) to discuss the unmet needs and challenges around maintenance of HIV-1 virologic suppression. Dr Ramgopal discusses challenges around stigma, social issues, tolerability, injection site reactions, and patient satisfaction with their current treatment regimen. Access an interview with Dr Moti […]
Moti Ramgopal, IDWeek 2022: Phase 3/3b FLAIR and ATLAS-2M pooled analysis – Efficacy and safety outcomes through week 96 by race
Long-acting cabotegravir + rilpivirine administered monthly or every 2 months is the first and only complete long-acting regimen recommended by treatment guidelines for the maintenance of HIV-1 virologic suppression. In this touchINFECTIOUS DISEASES interview, we met with Prof. Moti Ramgopal (Midway Research Center, FL, USA) to discuss a post hoc analysis of pooled outcomes for […]
Marina Klein, AIDS2022: Global health burden and the elimination of HIV, hepatitis B, and hepatitis C
There are number of challenges in the elimination of the three blood-borne viruses — HIV, hepatitis B (HBV), and hepatitis C (HCV). Treatment advances have been made with the introduction of highly effective antiviral agents into clinical practice, and prevention strategies. However, for worldwide elimination of these viruses, effective vaccines are required. Dr Marina Klein […]
Journal articles and more to your inbox
Get the latest clinical insights from touchINFECTIOUS DISEASESSign me up!